Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Mechanistic preclinical study with in vitro and mouse models showing ciprofol induces ferroptosis and enhances anti-PD-1 efficacy in HCC; no human clinical data or phase 1 trial reported, limiting evidence strength despite sound experimental design.
A perspective review raising questions about organoid models for cancer rather than reporting empirical results, mechanistic findings, or clinical outcomes with measured effect sizes.
Rigorous meta-analysis of 8 RCTs with reconstructed individual patient data and quantitative time-to-benefit modelling provides robust evidence on treatment duration, though findings are primarily analytical rather than from a new primary trial.
A comprehensive scoping review mapping the landscape of pancreatic cancer risk factors across multiple domains, identifying evidence concentration and gaps to inform future research priorities and prevention strategies.
Preclinical in vitro and xenograft study proposing a mechanism by which an existing drug may enhance chemotherapy, without clinical efficacy data or human evidence.
This is a mechanistic review summarizing preclinical evidence linking TMEM97/sigma-2 receptor to endocrine resistance pathways; the source explicitly states evidence remains preclinical and further investigation is needed.
A narrative review synthesizing observational and meta-analytic evidence on drug–ICI interactions, offering clinical recommendations on statin, PPI, and corticosteroid use during checkpoint inhibitor therapy, but not reporting new primary data.
In vitro mechanistic study demonstrating enhanced probiotic metabolite activity against colorectal cancer cells and angiogenesis, but lacking in vivo efficacy data, clinical endpoints, or human translation.